University Hospital of Psychiatry Zurich, Lenggstrasse 31, P.O. Box 1931, Zurich 8032, Switzerland.
Ther Adv Psychopharmacol. 2013 Apr;3(2):89-99. doi: 10.1177/2045125312464106.
The acceptance and use of long-acting depot antipsychotics has been shown to be influenced by the attitudes of patients and clinicians. Depot treatment rates are low across countries and especially patients with first-episode psychosis are rarely treated with depot medication. The aim of this article was to review the literature on patients' and clinicians' attitudes towards long-acting depot antipsychotics in subjects with first-episode psychosis.
A systematic search of Medline, Embase, PsycINF and Google Scholar was conducted. Studies were included if they reported original data describing patients' and clinicians' attitudes towards long-acting depot antipsychotic in subjects with first-episode psychosis.
Six studies out of a total of 503 articles met the inclusion criteria. Four studies conveyed a negative and two a positive opinion of clinicians toward depot medication. No systematic study directly addressed the attitude of patients with first-episode psychosis. Psychiatrists frequently presume that patients with first-episode psychosis would not accept depot medication and that depots are mostly eligible for chronic patients.
Full information of all patients especially those with first episode psychosis in a therapeutic relationship that includes shared decision-making processes could reduce the negative image and stigmatization attached to depots.
长效长效注射抗精神病药的接受和使用情况受到患者和临床医生态度的影响。长效治疗的比例在各国都很低，尤其是首发精神病患者很少使用长效药物治疗。本文的目的是回顾有关首发精神病患者对长效长效注射抗精神病药的态度的文献。
对 Medline、Embase、PsycINF 和 Google Scholar 进行了系统搜索。如果研究报告了描述首发精神病患者对长效长效注射抗精神病药的态度的原始数据，则将其纳入研究。
在总共 503 篇文章中，有 6 篇符合纳入标准。四项研究对临床医生对长效药物的态度表示负面，两项研究表示正面。没有系统的研究直接针对首发精神病患者的态度。精神科医生经常假设首发精神病患者不会接受长效药物治疗，而且长效药物主要适用于慢性患者。
在治疗关系中充分告知所有患者，特别是那些首发精神病患者，包括共同决策过程，可以减少对长效药物的负面印象和污名化。
